What's in MaaT Pharma's pipeline?

MaaT Pharma has 4 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with MaaT Pharma's portfolio?

Top competitors by shared drug class: Bogomolets National Medical University, King's College London.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/maat-pharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

MaaT Pharma — Portfolio Competitive Intelligence Brief

MaaT Pharma pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
MaaT013	MaaT013	phase 3	Microbiota therapeutic		Immunology / Gastroenterology

Therapeutic area mix

Gastroenterology · 1
Immunology / Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bogomolets National Medical University · 1 shared drug class
King's College London · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MaaT Pharma:

Cite this brief

Drug Landscape (2026). MaaT Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/maat-pharma. Accessed 2026-05-14.